Among these targeted therapeutic agents, TKI based on the EGFR mutations have been widely used in the clinic, and the ability to provide information on the EGFR mutations in clinical tumor tissues with the goal of guiding targeted therapy in a timely manner has become an important goal of lung cancer molecular detection [17–20]. This evidence concerns the gene EGFR and lung cancer.